Capricor Therapeutics HOPE-3 Phase 3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy to be Presented at AAN 2026

Key Takeaways

• Capricor Therapeutics will present Phase 3 HOPE-3 trial results for Deramiocel at the American Academy of Neurology 2026 Annual Meeting
• The late-breaking presentation suggests significant findings in treating Duchenne muscular dystrophy, a rare genetic muscle disorder
• Results could advance Deramiocel toward potential FDA approval as a cell-based therapy for DMD patients

---

SAN DIEGO, April 22, 2026 — Capricor Therapeutics (NASDAQ: CAPR) announced today that data from its pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel for Duchenne muscular dystrophy (DMD) will be presented as a late-breaking session at the American Academy of Neurology 2026 Annual Meeting.

Breakthrough in Duchenne Muscular Dystrophy Treatment

The biotechnology company, which specializes in developing transformative cell and exosome-based therapeutics for rare diseases, secured the prestigious late-breaking presentation slot, typically reserved for studies with significant clinical implications. Deramiocel represents a novel approach to treating DMD through cell-based therapy.

Duchenne muscular dystrophy affects approximately 1 in 3,500 to 5,000 male births worldwide and is characterized by progressive muscle degeneration and weakness. Current treatment options remain limited, making new therapeutic approaches critically important for patients and families.

IntelligenceRegulatory Impact▾

FDA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Regulatory Implications

The HOPE-3 trial represents Capricor’s most advanced clinical program, and positive results could position the company for regulatory submissions. The rare disease market for DMD is estimated to reach several billion dollars globally, with significant unmet medical need driving demand for innovative treatments.

Capricor’s cell-based approach using Deramiocel differentiates it from gene therapy and antisense oligonucleotide approaches currently in development or approved for DMD treatment. The therapy utilizes the company’s proprietary platform technology to potentially address muscle regeneration and function.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Next Steps and Timeline

The presentation at the American Academy of Neurology meeting will provide the medical community and investors with detailed efficacy and safety data from the Phase 3 trial. Depending on the results, Capricor may proceed with regulatory filings, potentially including a Biologics License Application (BLA) with the FDA.

The company’s stock has shown increased volatility ahead of the data presentation, reflecting investor anticipation for what could be a pivotal moment in the company’s development trajectory and the broader DMD treatment landscape.

---

Frequently Asked Questions

What is Deramiocel and how does it work for Duchenne muscular dystrophy?

Deramiocel is Capricor’s investigational cell-based therapy designed to treat Duchenne muscular dystrophy by potentially promoting muscle regeneration and improving muscle function through the company’s proprietary cell therapy platform.

When will Deramiocel be available to patients?

Availability depends on the HOPE-3 trial results and subsequent regulatory approval. If results are positive, Capricor may file for FDA approval, which typically takes 6-12 months for review, potentially making the treatment available in 2027 or later.

How does Deramiocel compare to existing DMD treatments?

Deramiocel represents a cell-based therapeutic approach, which differs from currently approved treatments like gene therapies (Elevidys) and antisense oligonucleotides (Exondys 51, Vyondys 53). The comparative effectiveness will be clearer once full trial results are presented.

Related coverage

• BioNTech doses first patient in Phase 1 pancreatic cancer mRNA vaccine trial
• Roche reports positive Phase 3 results for trontinemab in Alzheimer's disease
• Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update